✦ LIBER ✦

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

✍ Scribed by Peyman Hadji; Helmut Minne; Michael Pfeifer; Pierre Bourgeois; Patrice Fardellone; Angelo Licata; Vipul Devas; Daiva Masanauskaite; Elizabeth Barrett-Connor

Book ID: 113684412
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 527 KB
Volume: 75
Category: Article
ISSN: 1297-319X
DOI: 10.1016/j.jbspin.2007.07.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of once-monthl

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

✍ Ronald Emkey; Pierre D. Delmas; Michael Bolognese; Joao Lindolfo C. Borges; Feli 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Oral alendronate use and risk of cancer

Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study

✍ Chia-Hung Chiang; Chin-Chou Huang; Wan-Leong Chan; Po-Hsun Huang; Tzeng-Ji Chen; 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 183 KB

Treatment With Once-Weekly Alendronate 7

Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study

✍ Clifford J Rosen; Marc C Hochberg; Sydney L Bonnick; Michael McClung; Paul Mille 📂 Article 📅 2004 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 243 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi